Toenail onychomycosis: An important global disease burden

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 5, 2010, Pages 497-519

  Thomas, J ^a   Jacobson, G A ^a   Narkowicz, C K ^a   Peterson, G M ^a   Burnet, H ^b   Sharpe, C ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

Author keywords

dermatophytes; diagnosis; epidemiology; onychomycosis; toenail; treatment

Indexed keywords

AMOROLFINE; CICLOPIROX; FLUCONAZOLE; GRISEOFULVIN; IMIDAZOLE; ITRACONAZOLE; KERATIN; TERBINAFINE; TRIAZOLE;

AGING; CLINICAL FEATURE; DEBRIDEMENT; DIABETES MELLITUS; DISTOLATERAL SUBUNGUAL ONYCHOMYCOSIS; DRUG COST; ENDONYX ONYCHOMYCOSIS; ENVIRONMENTAL FACTOR; GENETICS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIFESTYLE MODIFICATION; NAIL BED; ONYCHOMYCOSIS; PATIENT CARE; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PROXIMAL SUBUNGUAL ONYCHOMYCOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SEX DIFFERENCE; SPORT; SUPERFICIAL WHITE ONYCHOMYCOSIS; TOENAIL ONYCHOMYCOSIS; TOTAL DYSTROPHIC ONYCHOMYCOSIS; TREATMENT FAILURE;

DRUG THERAPY, COMBINATION; FEMALE; FOOT DERMATOSES; HUMANS; MALE; NAILS; ONYCHOMYCOSIS; RECURRENCE; RISK FACTORS; TREATMENT FAILURE;

EID: 77956621286     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01107.x     Document Type: Review

References (173)

1. Elewski BE (2000) Onychomycosis: treatment, quality of life, and economic issues. American Journal of Clinical Dermatology, 1, 19 26.
2. Baran R, Kaoukhov A (2005) Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. Journal of the European Academy of Dermatology and Venereology, 19, 21 29.
3. Gupta AK, Baran E, Robert SRC (2003) Non-dermatophyte onychomycosis. Dermatologic Clinics, 21, 257 268.
4. Seebacher C, Brasch J, Abeck D et al. (2007) Onychomycosis. Mycoses, 50, 321 327. (Pubitemid 46920268)
5. Loo DS (2007) Onychomycosis in the elderly: drug treatment options. Drugs and Aging, 24, 293 302.
6. Foster KW, Ghannoum MA, Elewski BE (2004) Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. Journal of the American Academy of Dermatology, 50, 748 752.
7. Niewerth M, Korting HC (1999) Management of onychomycoses. Drugs, 58, 285 296.
8. Gupta AK, Ricci M-J (2006) Diagnosing onychomycosis. Dermatologic Clinics, 24, 365 369.
9. Finch JJ, Warshaw EM (2007) Toenail onychomycosis: current and future treatment options. Dermatologic Therapy, 20, 31 46.
10. Vander SMR, Hossain MA, Ghannoum MA (2003) Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. Infectious Disease Clinics of North America, 17, 87 112.
11. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R (2005) Epidemiology and clinical classification of onychomycosis. Journal of the European Academy of Dermatology and Venereology, 19, 8 12.
12. Sumikawa M, Egawa T, Honda I, Yamamoto Y, Sumikawa Y, Kubota M (2007) Effects of foot care intervention including nail drilling combined with topical antifungal application in diabetic patients with onychomycosis. The Journal of Dermatology, 34, 456 464.
13. Ogasawara Y, Hiruma M, Muto M, Ogawa H (2003) Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo. Mycoses, 46, 114 119.
14. Djeridane A, Djeridane Y, Ammar-Khodja A (2006) Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses, 49, 190 196.
15. Tan JS, Joseph WS (2004) Common fungal infections of the feet in patients with diabetes mellitus. Drugs and Aging, 21, 101 112.
16. Haas N, Sperl H (2001) A medical student discovers onychomycosis. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete, 52, 64 67.
17. Charif MA, Elewski BE (1997) A historical perspective on onychomycosis. Dermatologic Therapy, 3, 43 45.
18. Rippon JW (1988) Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 3rd edn.
19. Weidman FD (1927) The laboratory aspects of dermatophytosis. Archives of Dermatology, 15, 415 450.
20. Salgo PL, Daniel CR, Gupta AK, Mozena JD, Joseph SW (2003) Onychomycosis disease management. Medical Crossfire: debates, peer exchange and insights in medicine, 4, 1 17.
21. Elewski BE (1993) Tinea pedis and tinea manuum. In: Demis JD, ed. Clinical dermatology.
22. Ganor S, Perath MJ, Raubitschek F (1963) Tinea pedis in schoolchildren (an epidemiological study). Dermatologica, 126, 253 258.
23. Weinberg JM, Koestenblatt EK, Tutrone WD, Tishler HR, Najarian L (2003) Comparison of diagnostic methods in the evaluation of onychomycosis. Journal of the American Academy of Dermatology, 49, 193 197.
24. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC (1997) Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada-a multicenter survey of 2001 patients. International Journal of Dermatology, 36, 783 787.
25. Heikkila H, Stubb S (1995) The prevalence of onychomycosis in Finland. British Journal of Dermatology, 133, 699 703.
26. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC (2000) Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. Journal of American Academy of Dermatology, 43, 244 248.
27. Zaias N (1985) Onychomycosis. Dermatology Clinics, 3, 445 460.
28. Cohen JL, Scher RK, Pappert AS (1992) The nail and fungus infections. In: Elewski BE, ed. Cutaneous fungal infections.
29. Editorial (1979) Prevalence, morbidity, and cost of dermatological diseases. Journal of Investigative Dermatology, 73, 395 401.
30. Elewski BE, Charif MA (1997) Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Archives of Dermatology, 33, 1172 1173.
31. Ghannoum MA, Hajjeh RA, Scher R et al. (2000) A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. Journal of the American Academy of Dermatology, 43, 641 648.
32. Bramono K, Budimulja U (2005) Epidemiology of onychomycosis in Indonesia: data obtained from three individual studies. Japanese Journal of Medical Mycology, 46, 171 176.
33. Haneke E, Roseeuw D (1999) The scope of onychomycosis: epidemiology and clinical features. International Journal of Dermatology, 38, 7 12.
34. Tosti A, Hay R, Arenas-Guzman R (2005) Patients at risk of onychomycosis-risk factor identification and active prevention. Journal of the European Academy of Dermatology and Venereology, 19, 13 16.
35. Eliane Alves DFS, de Almeida LMM, Guilhermetti E, Mota AV, Rossi MR, Svidzinski EIT (2007) Frequency of onychomycoses caused by yeasts in Maringa, Parana, Brazil. Anais Brasileiros de Dermatologia, 82, 151 156.
36. Clemons KV, Schär G, Stover EP, Feldman D, Stevens DA (1988) Dermatophyte-hormone relationships: characterization of progesterone-binding specificity and growth inhibition in the genera Trichophyton and Microsporum. Journal of Clinical Microbiology, 26, 2110 2115.
37. Araújo AJG, Bastos OMP, Souza MAJ, Oliveira JCD (2003) Occurrence of onychomycosis among patients attended in dermatology offices in the city of Rio de Janeiro, Brazil. Anais Brasileiros de Dermatologia, 78, 299 308.
38. Gupta AK, Skinner AR (2004) Onychomycosis in children: a brief overview with treatment strategies. Paediatric Dermatology, 21, 74 79.
39. Gupta AK, Sibbald RG, Lynde CW et al. (1997) Onychomycosis in children: prevalence and treatment strategies. Journal of the American Academy of Dermatology, 36, 395 402.
40. Spitsyn VA, Novoselov AY, Makarov SV, Bychkovskaya LS, Pai GV, Voilokova FE, Alexeeva NV (2007) A role of the genetic factors in the onychomycosis development. Allele frequency distribution of polymorphic genes. Meditsinskaya Genetika, 6, 15 21.
41. Zaias N, Tosti A, Rebell G et al. (1996) Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. Journal of the American Academy of Dermatology, 34, 302 304.
42. Faergemann J, Correia O, Nowicki R, Ro B-I (2005) Genetic predisposition: understanding underlying mechanisms of onychomycosis. Journal of the European Academy of Dermatology and Venereology, 19, 17 19.
43. Faergemann J, Baran R (2003) Epidemiology, clinical presentation and diagnosis of onychomycosis. British Journal of Dermatology, 149, 1 4.
44. Nandedkar-Thomas MA, Scher RK (2005) An update on disorders of the nails. Journal of the American Academy of Dermatology, 52, 877 887.
45. Kaur R, Kashyap B, Bhalla P (2007) A five-year survey of onychomycosis in New Delhi, India: Epidemiological and laboratory aspects. Indian Journal of Dermatology, 52, 39 42.
46. Elewski BE (1998) Onychomycosis: pathogenesis, diagnosis and management. Clinical Microbiology Reviews, 11, 415 425.
47. Gupta AK, Konnikov N, Lynde CW et al. (1999) Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. European Journal of Dermatology, 9, 633 638.
48. Erbagci Z, Tuncel A, Zer Y, Balci I (2005) A prospective epidemiologic survey on the prevalence of onychomycosis and dermatophytosis in male boarding school residents. Mycopathologia, 159, 347 352.
49. Barua P, Barua S, Borkakoty B, Mahanta J (2007) Onychomycosis by Scytalidium dimidiatum in green tea leaf pluckers: report of two cases. Mycopathologia, 164, 193 195.
50. Gupta M, Sharma NL, Kanga AK, Mahajan VK, Tegta GR (2007) Onychomycosis: clinico-mycologic study of 130 patients from Himachal Pradesh, India. Indian Journal of Dermatology, Venereology and Leprology, 73, 389 392.
51. Roberts DT, Taylor WD, Boyle J (2003) Guidelines for treatment of onychomycosis. British Journal of Dermatology, 148, 402 410.
52. Detandt M, Nolard N (1995) Fungal contamination of the floors of swimming pools, particularly subtropical swimming paradises. Mycoses, 38, 509 513.
53. Brandi G (2007) Swimming pools and fungi: an environmental epidemiology survey in Italian indoor swimming facilities. International Journal of Environmental Health Research, 17, 197 206.
54. Gudnadóttir G, Hilmarsdóttir I, Sigurgeirsson B (1999) Onychomycosis in Icelandic swimmers. Acta Dermato-Venereologica, 79, 376 377.
55. Purim KSM, Bordignon GPF, Queiroz-Telles F (2005) Fungal infection of the feet in soccer players and non-athlete individuals. Revista Iberoamericana de Micologia: Organo de la Asociacion Espanola de Especialistas en Micologia, 22, 34 38.
56. Eisele SA (1994) Conditions of the toenails. The Orthopaedic Clinics of North America, 25, 183 188.
57. Caputo R, De Boulle K, Del Rosso J, Nowicki R (2001) Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. Journal of the European Academy of Dermatology and Venereology, 15, 312 316.
58. Baran R (2008) Review of antifungal therapy, part II: treatment rationale, including specific patient populations. Journal of Dermatological Treatment, 19, 168 175.
59. Gulec AT, Demirbilek M, Seckin D, Can F, Saray Y, Sarifakioglu E, Haberal M (2003) Superficial fungal infections in 102 renal transplant recipients: a case-control study. Journal of the American Academy of Dermatology, 49, 187 192.
60. Gupta AK, Ryder JE (2003) How to improve cure rates for the management of onychomycosis. Dermatologic Clinics, 21, 499 505.
61. Gupta AK, Konnikov N, MacDonald P et al. (1998) Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. British Journal of Dermatology, 139, 665 671.
62. Brem H, Sheehan P, Boulton AJM (2004) Protocol for treatment of diabetic foot ulcers. The American Journal of Surgery, 187, 1 10.
63. Dogra S, Kumar B, Bhansali A, Chakrabarty A (2002) Epidemiology of onychomycosis in patients with diabetes mellitus in India. International Journal of Dermatology, 41, 647 651.
64. Winston JA, Miller JL (2006) Treatment of onychomycosis in diabetic patients. Clinical Diabetes, 24, 160 166.
65. Gupta AK, Gupta MA, Summerbell RC et al. (2000) The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. Journal of the European Academy of Dermatology and Venereology, 14, 466 469.
66. Gupchup GV, Zatz JL (1999) Structural characteristics and permeability properties of the human nail: a review. Journal of Cosmetic Science, 50, 363 385.
67. Mahoney JM, Bennet J, Olsen B (2003) The diagnosis of onychomycosis. Dermatologic Clinics, 21, 463 467.
68. Kobayashi Y, Miyamoto M, Sugibayashi K, Morimoto Y (1999) Drug permeation through the three layers of the human nail plate. Journal of Pharmacy and Pharmacology, 51, 271 278.
69. Geyer AS, Onumah N, Uyttendaele H, Scher RK (2004) Modulation of linear nail growth to treat diseases of the nail. Journal of the American Academy of Dermatology, 50, 229 234.
70. Baran R, Belaich S, Beylot C et al. (1997) Comparative multicentre double-blind study of terbinafine (250 mg per day) vs. griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. Journal of Dermatological Treatment, 8, 93 97.
71. Shelley WB, Shelley ED (1992) A dermatologic diary: portrait of a practice. Cutis, 49, 180 184.
72. Uyttendaele H, Geyer A, Scher RK (2003) Brittle nails: pathogenesis and treatment. Journal of Drugs in Dermatology, 2, 48 49.
73. Doncker PD, Pierard GE (1994) Acquired nail beading in patients receiving itraconazole-an indicator of faster nail growth? A study using optical profilometry Clinical and Experimental Dermatology, 19, 404 406.
74. Hay R (2005) Literature review: onychomycosis. Journal of the European Academy of Dermatology and Venereology, 19, 1 7.
75. Baran R, Hay RJ, Tosti A, Haneke E (1998) A new classification of onychomycosis. British Journal of Dermatology, 139, 567 571.
76. Rodgers P, Bassler M (2001) Treating onychomycosis. American Family Physician, 63, 663 672. 677-668.
77. Murray SC, Dawber RPR (2002) Onychomycosis of toenails: orthopaedic and podiatric considerations. Australasian Journal of Dermatology, 43, 105 112.
78. Baran R, Faergemann J, Hay RJ (2007) Superficial white onychomycosis: a syndrome with different fungal causes and paths of infection. Journal of the American Academy of Dermatology, 57, 879 882.
79. Tosti A, Piraccini BM, Lorenzi S, Iorizzo M (2003) Treatment of nondermatophyte mold and Candida onychomycosis. Dermatologic Clinics, 21, 491 497.
80. Gupta AK, Ryder JE, Baran R, Summerbell RC (2003) Non-dermatophyte onychomycosis. Dermatologic Clinics, 21, 257 268.
81. Htwe TH, Mushtaq A, Robinson SB, Rocher RB, Khardori N (2007) Infection in the elderly. Infectious Disease Clinics of North America, 21, 711 743.
82. Fleckman P (2002) Onychomycosis: diagnosis and topical therapy. Dermatologic Therapy, 15, 71 77.
83. Gupta AK, Tu LQ (2006) Dermatophytes: diagnosis and treatment. Journal of the American Academy of Dermatology, 54, 1050 1055.
84. Scher RK, Tavakkol A, Sigurgeirsson B et al. (2007) Onychomycosis: diagnosis and definition of cure. Journal of the American Academy of Dermatology, 56, 939 944.
85. Arrese JE, Pierard GE (2003) Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology, 207, 255 260.
86. Lawry MA, Haneke E, Strobeck K, Martin S, Zimmer B, Romano PS (2000) Methods for diagnosing onychomycosis: a comparative study and review of the literature. Archives of Dermatology, 136, 1112 1116.
87. Holzberg M (2006) Common nail disorders. Dermatologic Clinics, 24, 349 354.
88. Gupta AK, Tu LQ (2006) Onychomycosis therapies: strategies to improve efficacy. Dermatologic Clinics, 24, 381 386.
89. Gupta AK, Lynde CW, Jain HC et al. (1997) A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. British Journal of Dermatology, 136, 786 789.
90. Lynde C (2001) Nail disorders that mimic onychomycosis: what to consider. Cutis, 68, 8 12.
91. Grover C, Reddy BSN, Uma CK (2005) Diagnosis of nail psoriasis: importance of biopsy and histopathology. British Journal of Dermatology, 153, 1153 1158.
92. Gupta AK, Shear NH (2000) A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety, 22, 33 52.
93. Levy LA (1997) Epidemiology of onychomycosis in special-risk populations. Journal of the American Podiatric Medical Association, 87, 546 550.
94. International Diabetes Federation (2003) Diabetes Atlas. Available at: http://www.eatlas.idf.org/ (accessed 24 November 2008).
95. Drake LA, Patrick DL, Fleckman P et al. (1999) The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. Journal of the American Academy of Dermatology, 1, 189 196.
96. Elewski BE (1997) The effect of toenail onychomycosis on patient quality of life. International Journal of Dermatology, 36, 754 756.
97. Hay RJ (2001) The future of onychomycosis therapy may involve a combination of approaches. British Journal of Dermatology, 145, 3 8.
98. Whittam LR, Hay RJ (1997) The impact of onychomycosis on quality of life. Clinical and Experimental Dermatology, 22, 87 89.
99. Gupta AK, Tu LQ (2006) Therapies for onychomycosis: a review. Dermatologic Clinics, 24, 375 379.
100. Gupta AK, Ryder JE, Skinner AR (2004) Treatment of onychomycosis: pros and cons of antifungal agents. Journal of Cutaneous Medicine and Surgery, 8, 25 30.
101. Sommer S, Sheehan-Dare RA, Goodfield MJD, Evans EGV (2003) Prediction of outcome in the treatment of onychomycosis. Clinical and Experimental Dermatology, 28, 425 428.
102. Roberts DT, Evans EG (1998) Subungual dermatophytoma complicating dermatophyte onychomycosis. British Journal of Dermatology, 138, 189 190.
103. Baran R (2008) Review of antifungal therapy and the severity index for assessing onychomycosis: Part I. Journal of Dermatological Treatment, 19, 72 81. (Pubitemid 351891547)
104. Thappa DM (2007) Current treatment of onychomycosis. Indian Journal of Dermatology, Venereology and Leprology, 73, 373 376.
105. Iorrizo M, Piraccini BM, Rech G, Tosti A (2005) Treatment of onychomycosis with oral antifungal agents. Expert Opinion on Drug Delivery, 2, 435 440.
106. Gupta AK, Ryder JE (2003) The use of oral antifungal agents to treat onychomycosis. Dermatologic Clinics, 21, 469 479.
107. Tinea of the nails (onychomycosis, tinea unguium). In: Therapeutic guidelines (2008).
108. Gupta AK, Ryder JE, Johnson AM (2004) Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. British Journal Dermatology, 150, 537 544.
109. Zhang AY, Camp WL, Elewski BE (2007) Advances in topical and systemic antifungals. Dermatologic Clinics, 25, 165 183.
110. Australian Medicines Handbook (2007). Nail Infections. Available at: http://www.amh.hcn.net.au/view.php (accessed 24 November 2008).
111. Fromtling RA (1988) Overview of medically important antifungal azole derivatives. Clinical Microbiology Reviews, 1, 187 217.
112. Gupta AK, Tomas E (2003) New antifungal agents. Dermatologic Clinics, 21, 565 576.
113. Chien RN, Yang LJ, Lin PY, Liaw Y-F (1997) Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology, 25, 103 107.
114. Drug Evaluation Monograph (2004) Fluconazole. Available at: http://www.pfizer.ca/english/our%20products/prescription%20pharmaceuticals/ default.asp?s=1&id=50&doc=enmonograph (accessed 21 October 2008).
115. Grant SM, Clissold SP (1989) Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs, 37, 310 344.
116. Willemsen M, De Doncker P, Willems J et al. (1992) Post treatment itraconazole levels in the nail. New implications for treatment in onychomycosis. Journal of the American Academy of Dermatology, 26, 731 735.
117. Chang C-H, Yinong Y-X, Kurth T et al. (2007) The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. The American Journal of Medicine, 120, 791 798.
118. Prescribing Information (2001) Lamisil (Terbinafine Hydrochloride Tablets). Available at: http://www.pharma.us.novartis.com/product/pi/pdf/ Lamisil-tablets.pdf (accessed 21 October 2008).
119. Evans EG, Sigurgeirsson B (1999) Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. British Medical Journal, 318, 1031 1035.
120. Heikkila H, Stubb S (2002) Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. British Journal of Dermatology, 146, 250 253.
121. Gupta AK, Einarson TR, Summerbell SC, Shear NH (1998) An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs, 55, 645 674.
122. Gupta AK, Ryder JE, Baran R (2003) The use of topical therapies to treat onychomycosis. Dermatologic Clinics, 21, 481 489.
123. Marty JPL (1995) Amorolfine nail lacquer: a novel formulation. Journal of the European Academy of Dermatology and Venereology, 5, 17 21.
124. Lauharanta J (1992) Comparative efficacy and safety of amorolfine nail lacquer 2% vs. 5% once weekly. Clinical and Experimental Dermatology, 17, 41 43.
125. Shuster S, Baran R (2001) Recurrence of fungal nail disease and the dissociation of relapse from re-infection. Acta Dermato-Venereologica, 81, 154 155.
126. Polak AM (1992) Preclinical data and mode of action of amorolfine. Clinical and Experimental Dermatology, 17, 8 12.
127. Reinel D, Clarke C (1992) Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clinical and Experimental Dermatology, 17, 44 49.
128. Product Monograph (2000) Penlac Nail Lacquer (Ciclopirox) Topical Solution. Available at: http://www.sanofi-aventis.ca/products/en/penlac.pdf (accessed 21 October 2008).
129. Bohn M, Kraemer K (2000) The dermatopharmacologic profile of ciclopirox 8% nail lacquer. Journal of the American Podiatric Medical Association, 10, 491 494.
130. Gupta AK, Joseph WS (2000) Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. Journal of the American Podiatric Medical Association, 90, 495 501.
131. Gupta AK, Fleckman P, Baran R (2000) Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology, 43, S70 S80.
132. Olafsson JH, Sigurgeirsson B, Baran R (2003) Combination therapy for onychomycosis. British Journal of Dermatology, 149, 15 18.
133. Gupta AK (2005) Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. Journal of Drugs in Dermatology, 4, 481 485.
134. Baran R, Feuilhade M, Datry A et al. (2000) A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. British Journal of Dermatology, 142, 1177 1183.
135. Lecha M (2001) Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain. British Journal of Dermatology, 145, 21 26.
136. Gupta AK, Lynch LE (2004) Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies. Cutis, 74, 5 9.
137. Avner S, Nir N, Henri T (2005) Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. Journal of Dermatological Treatment, 16, 327 330.
138. Jaiswal A, Sharma RP, Garg AP (2007) An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian Journal of Dermatology, Venereology and Leprology, 73, 393 396.
139. Harman S, Ashbee HR, Evans EGV (2004) Testing of antifungal combinations against yeasts and dermatophytes. The Journal of Dermatological Treatment, 15, 104 107.
140. Arrese JE, Pierard-Franchimont C, Pierard GE (2001) A plea to bridge the gap between antifungals and the management of onychomycosis. American Journal of Clinical Dermatology, 2, 281 284.
141. Pierard GE, Pierard-Franchimont C, Arrese JE (2000) The boosted antifungal topical treatment (BATT) for onychomycosis. Medical Mycology, 38, 391 392.
142. Pierard GE, Pierard-Franchimont C, Arrese JE (2000) The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology, 200, 185 187.
143. Anonymous (2007) Toenail fungus: drill to kill. Delivering antifungal medicine through holes in the infected nail may make it more effective. Harvard health letter from Harvard Medical School, 32, 6.
144. Gupta AK, Daniel CR (1998) Factors that may affect the response of onychomycosis to oral antifungal therapy. The Australasian Journal of Dermatology, 39, 222 224.
145. Nolting SK, Carazo JS, De Boulle K, Lambert JR (1998) Oral treatment schedules for onychomycosis: a study of patient preference. International Journal of Dermatology, 37, 454 456.
146. Hu Y, Yang L-J, Wei L et al. (2005) Study on the compliance and safety of the oral antifungal agents for the treatment of onychomycosis. Zhonghua Liuxingbingxue Zazhi, 26, 988 991.
147. Gupta AK, Lambert J (1999) Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. International Journal of Dermatology, 38, 53 64.
148. Marty JPL, Lambert J, Jaeckel A, Adjadj L (2005) Treatment costs of three nail lacquers used in onychomycosis. The Journal of Dermatological Treatment, 16, 299 307.
149. Gupta AK, Humke S (2000) The prevalence and management of onychomycosis in diabetic patients. European Journal of Dermatology, 10, 379 384.
150. Lavery LA, van Houtum WH, Ashry HR, Armstrong DG, Jacqueline A (1999) Diabetes-related lower-extremity amputations disproportionately affect Blacks and Mexican Americans. Southern Medical Journal, 92, 593 599.
151. Australasian Podiatry Council (2004) Foot health week 2004, diabetes? Check your feet. Available at: http://www.feet.org.au/archive/2004/index.html (accessed 28 October 2008).
152. Davis WA, Norman PE, Bruce DG et al. (2006) Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 49, 2634 2641.
153. Hayutin AM (2007) How population aging differs∼across countries: a briefing on global demographics. Stanford Centre on longevity. Available at: http://longevity.stanford.edu/files/BriefingGlobalDemographics-0.pdf (accessed 28 October 2008).
154. Sinclair R (1998) What is the cost of onychomycosis? The Australasian Journal of Dermatology, 39, 131 132.
155. Gupta AK, Lynch LE (2004) Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis, 74, 10 15.
156. Yazdanparast SA, Barton RC (2006) Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. Journal of Medical Microbiology, 55, 1577 1581.
157. Pierard GE (2006) Spores, sporodochia and fomites in onychomycosis. Dermatology, 2, 169 172.
158. Korting HC, Schafer-Korting M, Zienicke H, Georgii A, Ollert MW (1993) Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrobial Agents and Chemotherapy, 37, 2064 2068.
159. Faergemann J, Anderson C, Hersle K et al. (1995) Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology, 32, 750 753.
160. Villars VV, Jones TC (1992) Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. British Journal of Dermatology, 126, 61 69.
161. Galimberti R, Kowalczuk A, Flores V, Squiquera L (1996) Onychomycosis treated with a short course of oral terbinafine. International Journal of Dermatology, 35, 374 375.
162. Drake LA, Shear NH, Arlette JP et al. (1997) Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. Journal of the American Academy of Dermatology, 37, 740 745.
163. Goodfield MJ, Andrew L, Evans EG (1992) Short-term treatment of dermatophyte onychomycosis with terbinafine. British Medical Journal, 304, 1151 1154.
164. Sigurgeirsson B, Elewski BE, Rich PA, Opper C, Cai B, Nyirady J, Bakshi R (2006) Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. Journal of Dermatological Treatment, 17, 38 44.
165. De Backer M, De Keyser P, De Vroey C, Lesaffre E (1996) A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mgday vs. itraconazole 200 mgday-a double-blind comparative trial. British Journal of Dermatology, 134, 16 17.
166. Shemer A, Nathansohn N, Kaplan B, Gilat D, Newman N, Trau H (1999) Open randomized comparison of different itraconazole regimens for the treatment of onychomycosis. Journal of Dermatological Treatment, 10, 245 249.
167. Sigurgeirsson B, Olafsson JH, Steinsson JP, Paul C, Billstein S, Evans EG (2002) Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Archives of Dermatology, 138, 353 357.
168. De Cuyper C, Hindryckx PH (1999) Long-term outcomes in the treatment of toenail onychomycosis. British Journal of Dermatology, 141, 15 20.
169. Havu V, Heikkila H, Kuokkanen K et al. (2000) A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. British Journal of Dermatology, 142, 97 102.
170. Ling MR, Swinyer LJ, Jarratt MT et al. (1998) Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology, 38, 95 102.
171. Crawford F, Young P, Godfrey C, Bell-Syer SE, Hart R, Brunt E, Russell I (2002) Oral treatments for toenail onychomycosis: a systematic review. Archives of Dermatology, 138, 811 816.
172. Gupta AK (1998) Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. PharmacoEconomics, 13, 243 256.
173. Cordoro KM, Ganz JE (2005) Training room management of medical conditions: sports dermatology. Clinics in Sports Medicine, 24, 565 598.